Literature DB >> 26077730

Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous.

Annie Drapeau, David Fortin1.   

Abstract

Malignant brain tumors including primary brain tumors (e.g., glioblastoma multiforme) and metastases, are aggressive and lethal entities for the majority of affected patients. Current standard treatments involving combinations of surgery, radiotherapy and systemic chemotherapy offer only modest improvements in survival. Faced with dismal survival, great efforts are deployed to find interesting treatment alternatives. However, the blood-brain barrier (BBB) and the blood-tumor barrier (BTB) remain great obstacles to significant drug delivery to brain tumors. The need to optimize delivery strategies for better patient outcome in the treatment of malignant brain tumors is well acknowledged. Certain interesting strategies use surgical or physical techniques to enhance the distribution of therapeutic agents to the central nervous system. The following strategies will be discussed in this review: intra-arterial delivery, osmotic BBB disruption, intranasal delivery, convection-enhanced delivery and osmotic pumps, implanted polymers, magnetic microspheres and ultrasound BBB disruption. The purpose of this paper is to review the importance of the BBB and the BTB and to review the current status and future perspectives of these delivery procedures.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26077730     DOI: 10.2174/1568009615666150616123548

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  7 in total

1.  MR image-guided delivery of cisplatin-loaded brain-penetrating nanoparticles to invasive glioma with focused ultrasound.

Authors:  Kelsie F Timbie; Umara Afzal; Abhijit Date; Clark Zhang; Ji Song; G Wilson Miller; Jung Soo Suk; Justin Hanes; Richard J Price
Journal:  J Control Release       Date:  2017-03-11       Impact factor: 9.776

Review 2.  EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise.

Authors:  Manfred Westphal; Cecile L Maire; Katrin Lamszus
Journal:  CNS Drugs       Date:  2017-09       Impact factor: 5.749

3.  The Role of miR-330-3p/PKC-α Signaling Pathway in Low-Dose Endothelial-Monocyte Activating Polypeptide-II Increasing the Permeability of Blood-Tumor Barrier.

Authors:  Jiahui Liu; Libo Liu; Shuo Chao; Yunhui Liu; Xiaobai Liu; Jian Zheng; Jiajia Chen; Wei Gong; Hao Teng; Zhen Li; Ping Wang; Yixue Xue
Journal:  Front Cell Neurosci       Date:  2017-12-19       Impact factor: 5.505

4.  Rationale and design of the 500-patient, 3-year, and prospective Vigilant ObservatIon of GlIadeL WAfer ImplaNT registry.

Authors:  Kevin O Lillehei; Steven N Kalkanis; Linda M Liau; Dellann Elliott Mydland; Jeffrey Olson; Nina A Paleologos; Timothy Ryken; Tania Johnson; Evan Scullin
Journal:  CNS Oncol       Date:  2017-12-05

5.  Management of Primary Central Nervous System Lymphoma Using Intra-Arterial Chemotherapy With Osmotic Blood-Brain Barrier Disruption: Retrospective Analysis of the Sherbrooke Cohort.

Authors:  Christian Iorio-Morin; Gérald Gahide; Christophe Morin; Davy Vanderweyen; Marie-André Roy; Isabelle St-Pierre; Karine Massicotte-Tisluck; David Fortin
Journal:  Front Oncol       Date:  2021-01-20       Impact factor: 6.244

6.  Nanotherapy and Reactive Oxygen Species (ROS) in Cancer: A Novel Perspective.

Authors:  Peter Brenneisen; Andreas S Reichert
Journal:  Antioxidants (Basel)       Date:  2018-02-22

7.  European Mistletoe (Viscum album) Extract Is Cytotoxic to Canine High-Grade Astrocytoma Cells In Vitro and Has Additive Effects with Mebendazole.

Authors:  Anna Wright; Rie Watanabe; Jey W Koehler
Journal:  Vet Sci       Date:  2022-01-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.